Syndax Pharmaceuticals (SNDX) Tops Q1 EPS by 6c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.59), $0.06 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $0 versus the consensus estimate of $800 thousand.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Creatd files Form S-1 and reports Q1 2026 financial results
• Carnival shares drop despite earnings beat on weak guidance